Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes

Annals of Hematology

Volumn 87, Issue 2, 2008, Pages 139-145

  Zuckermann, J ^a,b   Moreira, L B ^a,b   Stoll, P ^a   Moreira, L M ^a   Kuchenbecker, R S ^b   Polanczyk, C A ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Antibiotic policy; Compliance; Critical pathway; Febrile neutropenia; Treatment guidelines

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; GENTAMICIN; GLYCOPEPTIDE; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; VANCOMYCIN;

ADULT; ARTICLE; BRAZIL; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; BRAZIL; CASE-CONTROL STUDIES; CRITICAL PATHWAYS; FEMALE; FEVER; GUIDELINE ADHERENCE; HOSPITALS, TEACHING; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 38049141184     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0390-7     Document Type: Article

References (30)

1. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103(9):1916-1924
2. Paul M, Soares-Weiser K, Leibovici L (2003) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: Systematic review and meta-analysis. BMJ 326(7399):1111
3. Sipsas NV, Bodey GP, Kontoyiannis DP (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103(6):1103-1113
4. Klastersky J (2004) Empirical antifungal therapy. Int J Antimicrob Agents 23(2):105-112
5. de Lalla F (2003) Outpatient therapy for febrile neutropenia: Clinical and economic implications. Pharmacoeconomics 21(6):397-413
6. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J (1999) Clinical guidelines: Potential benefits, limitations, and harms of clinical guidelines. BMJ 318(7182):527-530
7. Worrall G, Chaulk P, Freake D (1997) The effects of clinical practice guidelines on patient outcomes in primary care: A systematic review. Can Med Assoc J 156(12):1705-1712
8. Fine MJ, Stone RA, Lave JR, Hough LJ, Obrosky DS, Mor MK et al (2003) Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: A randomized controlled trial. Am J Med 115(5):343-351
9. Polanczyk CA, Biolo A, Imbof BV, Furtado M, Alboim C, Santos C et al (2003) Improvement in Clinical outcomes in Acute Coronary Syndromes After the Implementation of a Critical Pathway. Crit Pathways Cardiol 2(4):222-230
10. Cook DJ, Greengold NL, Ellrodt AG, Weingarten SR (1997) The relation between systematic reviews and practice guidelines. Ann Intern Med 127(3):210-216
11. Freemantle N (1996) Are decisions taken by health care professionals rational? A non systematic review of experimental and quasi experimental literature. Health Policy 38(2):71-81
12. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA (1998) Closing the gap between research and practice: An overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 317(7156):465-468
13. Feder G, Eccles M, Grol R, Griffiths C, Grimshaw J (1999) Clinical guidelines: Using clinical guidelines. BMJ 318(7185):728-730
14. Mol PG, Wieringa JE, Nannanpanday PV, Gans RO, Degener JE, Laseur M et al (2005) Improving compliance with hospital antibiotic guidelines: A time-series intervention analysis. J Antimicrob Chemother 55(4):550-557
15. Nijhuis CO, Kamps WA, Daenen SM, Gietema JA, van der Graaf WT, Groen HJ et al (2005) Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 23(30):7437-7444
16. Vidal L, Paul M, Ben-Dor I, Pokroy E, Soares-Weiser K, Leibovici L (2004) Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 4:CD003992
17. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P et al (2005) Fluoroquinolone resistance of Escherichia coli at a cancer center: Epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24(2):111-118
18. Escalante CP, Weiser MA, Manzullo E, Benjamin R, Rivera E, Lam T et al (2004) Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 12(9):657-662
19. Pon D (1996) Service plans and clinical interventions targeted by the oncology pharmacist. Pharm Pract Manag Q 16(1):18-30
20. Zusman RM, Chesebro JH, Comerota A, Hartmann JR, Massin EK, Raps E et al (1999) Antiplatelet therapy in the prevention of ischemic vascular events: Literature review and evidence-based guidelines for drug selection. Clin Cardiol 22(9):559-573
21. Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: A prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12(8):555-560
22. Viscoli C (1998) The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 41(Suppl D):65-80
23. Link H, Bohme A, Cornely OA, Hoffken K, Kellner O, Kern WV et al (2003) Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 82(2):S105-S117
24. Freifeld AG, Elting L, Montoya JG, Noskin G, Roston K, Segal BH (2005) Clinical practice guidelines in oncology. National Comprehensive Cencer Network 2005 August 31 [cited 2005 Nov 1];V1
25. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al (2002) guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730-51
26. Santolaya ME, Rabagliati R, Bidart T, Paya E, Guzman AM, Morales R et al (2005) Consensus: Rational approach towards the patient with cancer, fever and neutropenia. Rev Chilena Infectol 22(Suppl 2):S79-113
27. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA et al (1999) Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282(15):1458-65
28. Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, Mokkink H (1998) Attributes of clinical guidelines that influence use of guidelines in general practice: Observational study. BMJ 317(7162):858-61
29. Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10(2):316-22
30. Paul M, Borok S, Fraser A, Vidal L, Leibovici L (2005) Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 55(4):436-44